Alongside news of our Q2 2024 earnings and pipeline progress yesterday, we announced the promotion of Christopher Frankenfield to chief financial officer while continuing to serve in his role as chief operating officer. Chris has been integral to guiding Xilio's strategic growth since he joined us in 2021, and we are confident in his continued leadership as we advance our robust pipeline of tumor-activated immunotherapies to treat cancer. https://lnkd.in/eDzrgytg
Xilio Therapeutics, Inc.’s Post
More Relevant Posts
-
✅ Are you attending ESMO - European Society for Medical Oncology 2024? 💥 Well, we are too! We’ve got something special for you, discover how CGW Plus is transforming oncology by offering powerful tools that simplify oncology workflows, making your operations more efficient, effective, and compliant.
Are you attending ESMO 2024? Well, we are too! We’ve got something special for you, discover how CGW Plus is transforming oncology by offering powerful tools that simplify oncology workflows, making your operations more efficient, effective, and compliant. Visit Velsera at booth #433 for exclusive insights, hands-on demos, and a chance to connect with our experts. Let's collaborate to advance cancer research! Schedule a meeting here: https://lnkd.in/gxna3Sec
To view or add a comment, sign in
-
-
"Empower early detection, ignite hope. Join us at #KDxDiagnostics this Bladder Cancer Awareness Month and make a difference with our innovative diagnostic solutions. Together, let’s save lives. 💙 #KnowYourRisk #BladderCancerAwareness"
To view or add a comment, sign in
-
-
Ready for #ASCO24 next week? In preparation, I've been reviewing abstract titles and generating my action plan. Check out the expected highlights below – and reach out for the full article. Beyond the headline papers, I will be following: 🫁 Developments in NSCLC (particularly with KRAS inhibitors and ADCs). Can we move the needle, or do we need to manage expectations? 🥊 🥊 postMONARCH: Does re-challenge with a CDK4/6 inhibitor after progression at 1L make sense? 🔥 Other exciting topics: The latest on MCED for cancer screening, advancements in AI improving cancer care, and further evidence/review of ctDNA in optimizing decision-making. Looking forward to following the latest and sharing insights from ASCO 2024 with Beyond Blue!
🔬 As #ASCO2024 fast approaches, we're thrilled to join the global community showcasing the latest advances in oncology. This year's event promises to be as ground-breaking as ever, and our #oncology team Beyond Blue has been working diligently to bring you the key topics coming up. 🎤 Siobhan Davies will be reporting back real-time insights as the event unfolds from May 31st onwards and, as always, we will be sharing our key highlights and implications post-ASCO. 📩 Get in touch today for full access to our 'Sneak Peek' article and to find out more from our oncology team oncology@beyondblueinsight.com
To view or add a comment, sign in
-
-
Let me know if you would like to join us to learn more about diagnosing lung cancer Earlier!
There's still time to register! Join us on TOMORROW at 7pm for our "Time to Treat" Webinar in partnership with Biodesix, Inc. Dr. Sonali Sethi will discuss The Clinical and Economic Benefits of Efficiently Diagnosing Lung Cancer by utilizing Biodesix, Inc.’s Nodify Lung® and Noah Medical's Galaxy System™. Register now as space is limited! https://hubs.ly/Q02qPj2w0
To view or add a comment, sign in
-
-
Fragmentomics is a wonderful concept in liquid biopsy. Similar to a muti-omics solution, fragmentomics looks at the composition of cf-DNA (length profile traditionally) to identify the ct-DNA profile. From here you can infer all sorts of useful information about the patients cancer. What makes it different from multi-omics is that you use the same DNA assay as for standard liquid biopsy. So twice the bang for a single buck! Seems like most ct-detection projects will soon be adding this to their arsenal. Up next, how to merge fragmentomics analysis with traditional variant calling? Im sure somebody's done it already...!
Susan Tousi, CEO of DELFI Diagnostics, joins Nasdaq to discuss how Delfi helps people live longer, healthier, cancer-free lives by detecting cancer early. Watch more: https://lnkd.in/e3KfEPEk
To view or add a comment, sign in
-
🎧 {NEW} We're giving you a challenge: to spark joy and strengthen connections within your teams and communities over the next 90 days. Through intentional acts of celebration and connection, we explore the transformative power of shared experiences in fostering a sense of belonging and support. As part of this journey, the Leadership Vision team shares their participation in a deeply meaningful 5k race for breast cancer awareness, marking a tradition of resilience and unity. This episode exemplifies how collective actions can significantly impact our sense of community and belonging. 🔗 Join us in embracing this challenge to create lasting, positive change. https://buff.ly/3U8e6Si
To view or add a comment, sign in
-
-
🏅 TOP EXECUTIVE COACH OF 2024 - IAOTP | BESTSELLING AUTHOR | CONSULTANT & SPEAKER | Elevating leaders & teams with executive/power dynamics coaching & strategic consulting backed by 25+ years of battle-tested expertise.
October is Breast Cancer Awareness Month—a time to not only support those affected but also to lead by example. 💖 As leaders, you have the power to inspire action, raise awareness, and promote early detection. It’s not just about showing support; it’s about leading with compassion, courage, and a commitment to making a difference. 🎀 How will you lead the fight against breast cancer this month? Let’s spark conversations, encourage our teams and communities to take action, and stand together in this cause. #TinnaJackson #ExecutiveEQ #BreastCancerAwareness #LeadershipInAction #LeadWithCompassion #EarlyDetectionSavesLives #SupportTheFight #StrongerTogether
To view or add a comment, sign in
-
-
Today’s FDA approval marks a pivotal achievement in our ongoing collaboration with patients, advocates, medical professionals and researchers to help address concerns around disease recurrence in #earlybreastcancer. As we celebrate this new milestone in our 35-year long journey to address the needs of people touched by breast cancer, we reflect on the personal and collective drivers behind our work in this space. Take a look at our sources of inspiration and share with us: what fuels your efforts in #breastcancer? #bcsm #ReimaginingMedicine, together
What inspires our efforts in breast cancer?
To view or add a comment, sign in
-
"Relive the highlights of Day 1 at the E3 International Cancer Conference! 🎥 From inspiring keynote speeches to engaging panel discussions, catch a glimpse of the groundbreaking moments that unfolded. Stay tuned for more insights and revelations as we continue to drive progress in cancer care. #E3Conference #Day1Highlights #CancerCare"
To view or add a comment, sign in
-
What a brilliant awareness video of retinoblastoma from Harry to kickstart Childhood Cancer Awareness Month! To learn how you can get involved in the awareness month, head over to our website: https://buff.ly/2PMBcP3
To view or add a comment, sign in